Navigation Links
FDA clears biomarker test for ovarian cancer
Date:9/6/2011

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

The FDA granted 510(k) clearance for marketing and use of a combination of blood tests for proteins HE4 and CA125 with the Risk of Ovarian Malignancy Algorithm (ROMA). Research demonstrates that examining levels of HE4 and CA125 using the ROMA algorithm shows the highest accuracy in determining ovarian cancer risk in pre- and post-menopausal women.

The combination of blood tests and the ROMA algorithm were developed through the research of a team led by Richard G. Moore, MD, a gynecologic oncologist with the Program in Women's Oncology at Women & Infants Hospital of Rhode Island and director of the Center for Biomarkers and Emerging Technology. Dr. Moore is the lead author of a multi-center study investigating the use of HE4 and CA125 to determine ovarian cancer risk.

"Using ROMA with HE4 and CA125 significantly improves our ability to identify women who are at high or low likelihood of ovarian cancer when they present with an ovarian cyst or mass," explained Dr. Moore, who is also an assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University.

The CA125 test has been the gold standard for monitoring patients diagnosed with ovarian cancer. The test, however, is limited in its sensitivity and specificity as well as its ability to detect all types of ovarian cancer. HE4 has been shown to be elevated in epithelial ovarian cancers, the most common type of ovarian cancer, but not elevated in many benign gynecologic diseases. Combining physician assessment with the independently validated ROMA algorithm more accurately stratifies benign disease from ovarian cancer in women who present with a pelvic mass. It also enables physicians to identify those patients at high likelihood of m
'/>"/>

Contact: Susan McDonald
slmcdonald@womenandinfants.org
401-681-2816
Women & Infants Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
2. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
3. Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children
4. Refocusing the boom in biomarker research
5. Researchers identify early biomarker for future atopy in asymptomatic children
6. Researchers find CDT biomarker ineffective for identifying unhealthy alcohol use
7. Study of biomarker development in mice provides a roadmap for a similar approach in humans
8. Tie Between Biomarkers, Disease Often Overstated, Scientists Say
9. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
10. BATTLE researchers identify new biomarkers for EGFR inhibition
11. Biomarker-driven science at the heart of new ACRIN-ECOG structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... First Choice Emergency Room , the ... United States, named Richard Daniels, DO the Medical Director ... , “We are pleased to announce that Dr. Daniels ... facility in Pflugerville,” said Dr. James M. Muzzarelli, Executive ... Dr. Daniels received his undergraduate degree from Brigham Young ...
(Date:8/20/2014)... 2014 Kowa Optimed returns after a ... debut the new SL-17 portable slit lamp. , The ... LED source controlled by an illuminated thumb wheel for ... uses commercially available AAA rechargeable and dry cell batteries, ... requiring batteries designed specifically for the device. The new ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3
... , TUESDAY, Oct. 11 (HealthDay News) -- A small, preliminary study ... intestines -- a potential sign that the pills might reduce the ... be done, and the researchers aren,t yet recommending that people head ... meal times. "If you want to add ginger to part ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 11 (HealthDay ... raises the risk for both breast and ovarian cancer are ... new study indicates. Those other women include both women ... of breast and ovarian cancer, and women without ...
... A team of scientists led by a Penn State ... an alternative method of molecular depth profiling -- a ... such as human tissue, nanoparticles, and other substances. In ... modeling to show the effectiveness and limitations of the ...
... is exploring the ethical challenges that clinicians and ... in the United States. The project is supported by ... Program. Most of the estimated 11 million undocumented ... are ineligible for public insurance programs. They are prohibited ...
... intersection density and well-connected streets in towns and cities ... according to a Queen,s University study. "We,ve known ... a high density of intersections in a given areahelps ... and more efficient for them to walk to work ...
... TUESDAY, Oct. 11 (HealthDay News) -- Nearly 90 percent of ... well-being, according to a new national poll of 1,000 voters. ... also revealed that by having routine mammograms, women gain a ... that poll results show that nearly nine in 10 women ...
Cached Medicine News:Health News:Ginger Supplements Might Ease Inflammation Linked to Colon Cancer 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 3Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 4Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 2Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 3Health News:New project examines medical safety net for undocumented patients 2Health News:Women Say Mammograms Give Them Sense of Control: Survey 2
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... , August 19, 2014 ,Weight ... Pipeline Assessment, 2014, report provides comprehensive insights about phase ... A key objective of the report is to establish ... III pipeline drugs across the different countries and regions. ... thoroughly, the report also provides details on the drug ...
(Date:8/18/2014)... Gamida Cell , a world ... today that it has signed an investment and option agreement ... Novartis " ) . According to the agreement, ... return will receive 15% equity and an option to fully ... period of time following achievement of certain milestones connected to ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4
... - Both co-primary endpoints, Wake After Sleep Onset and ... Sleep, were met at both doses - Evotec to ... 10am EST) today , HAMBURG, Germany | OXFORD, England, ... today positive top-line,results from its first phase II clinical ...
... Summary: Follow-up RAS data presented at ASCO , ... gave,a presentation titled "RAS peptide vaccination in resected,pancreatic ... long term survival" at ASCO's (American Society of ... of 23 resected pancreatic cancer patients,immunized in the ...
Cached Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine 2
... MJS anatomic knee ... enhance durability, minimize polyethylene ... surfaces, to minimize contact ... and to achieve a ...
Simplified Design-Based on 15 Years of Experience...
... The result of more than a ... is based on a comprehensive study of ... resection, and tibial insert retrieval analysis.,As a ... axial rotation and motion patterns in total ...
... True to its leadership role within ... the clinical experience of the industry's leading ... Platform Knee System, with the clinically proven ... world's leading rotating platform knee. ,The result ...
Medicine Products: